Patent ID: 9682111
Date: 2017-06-20
CPC Classifications: A61K

Claim:
1. A method for treating Parkinson's disease comprising decreasing Parkinson's disease gene alpha-Synuclein in a subject, comprising administrating to the subject an effective amount of a compound selected from: 7β, 13S-Dihydroxylabda-8(17)-14-dien-19-oic acid; 1-Naphthalenecarboxylic acid, decahydro-1,4a-dimethyl-6-methylene-5-[(1E)-3-oxo-1-butenyl]-, (1S, 4aS, 5S, 8aR)-; Platyclolactonic acid; 14,15-bisnor-8(17)-labdene-16,19-dioic acid; 1-oxo-3β-hydroxytotarol; 6, 7-dehydro-sandaracopimaric acid; Sandaracopimaric acid; 12, 13, 14-trihydroxyl-12, 15-epoxyabda-8(17)-en-19-oic acid; Isopimaric acid; 7α-Hydroxysandaracopimaric acid; 15, 16-Dihydroxy-8(17), 13(E)-labdadien-19-oic acid; 13-Epicupressic acid; Isocupressic acid; Sandaracopimaradiene-3β, 18-diol; 14(R), 15-Dihydroxy-8(17), 12(E)-labdadien-19-oic acid; 14, 15-Bisnor-8(17), 12E-labdadien-19-oic acid methyl ester; Naphthalenecarboxylic acid, decahydro-1,4a-dimethyl-6-methylene-5-[(2E)-3-methyl-4-oxo-2-butenyl]-, (1S, 4aR, 5S, 8aR)-; and Imbricatolic acid.